Pramipexole /tid
Phase 2Small molecule
Pramipexole /tid is one of 25 small molecule programs targeting Obsessive-Compulsive Disorder. It is currently in Phase 2.
1
Indications
1
Total Trials
1
Active Trials
24
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
28 competitors in Obsessive-Compulsive Disorder
#DrugCompanyPhaseTrials
1Lexapro
AbbVieApproved
Ingrezza
Neurocrine BiosciencesApproved
Revia
TevaApproved
Prozac
VVitae Pharmaceuticals Inc., an Allergan affiliate
Approved
Seroquel
EEngelhard Arzneimittel GmbH & Co.KG
Approved
Celexa
AbbVieApproved
Zoloft
VViatris Specialty LLC
Approved
Topamax
WWim Janssens
Approved
Tasmar
BBausch Health Americas, Inc.
Approved
Ativan
BBausch Health Americas, Inc.
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Obsessive-Compulsive Disorder1 trial
Safety and Efficacy of Pramipexole Treatment in Resistant Obsessive-Compulsive Disorder (OCD)
Recruiting·—·Phase 2·NCT06611592·48 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Pramipexole /tid. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details